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Background: A recent meta-analysis has suggested that patients aged >65 have worse outcomes with radiocephalic
arteriovenous fistulas (RCAVFs) compared with brachiocephalic arteriovenous fistulas (BCAVFs). We hypothesized that
outcomes in patients aged>80—a rapidly expanding cohort within this elderly group—might be skewing the results, and
that age>65 may not be a contraindication to RCAVF formation. This study examined the effect of age group (<65, 65
to 79, >80) on functional outcomes (use; primary and secondary functional patency) in RCVAFs and BCAVFs.
Methods:We identified the outcomes of all patients undergoing a first surgical access procedure for a RCAVF or BCVAF
between January 1, 2000, andDecember 31, 2005.We examined the effect of age and other factors including sex, diabetes
mellitus, hypertension, late referral (<3 months before dialysis), dialysis before surgical access, preoperative duplex
ultrasound imaging, and ethnicity on non-AVF use and primary and secondary functional AVF patency. Logistic
regression and Cox proportional hazards regression models were used.
Results: From a total of 658 patients, 361 had a RCAVF, and 297 had a BCAVF. Their median age was 68.5 years
(interquartile range [IQR], 54.4 to 76.5 years), and 288 (43.8%) were aged <65 years, 274 (41.6%) were 65 to 79, and
96 (14.6%) were>80. Age did not influence the site of the first surgical access (P .874). Only 85.7% of patients actually
progressed to hemodialysis, and the RCAVF or BCAVF in 45.7% of those was never used for dialysis. Female sex (hazard
ratio [HR], 2.24; 95% confidence interval [CI] 1.387 to 3.643; P .001) was the only factor associated with an increase
risk of RCAVF nonuse, whereas diabetes (HR, 2.095; 95% CI, 1.261 to 3.482; P  .004) was the only factor associated
with an increase risk of BCAVF nonuse. The respective primary patency rates at 1 and 2 years for RCAVFs were 46.0%
and 27.1% for patients <65, 47.0% and 36.0% for those 65 to 79, and 45.7% and 38.1% for those >80. Only female sex
(HR, 1.679; 95% CI, 1.261 to 2.236; P .001) and prior hemodialysis (HR, 1.363; 95% CI, 1.0.29 to 1.804; P .031)
were associated with loss of patency of RCAVFs. The primary functional patency rates for BCAVFs at 1 and 2 years were
39.3% and 31.0% for those <65 years; 53.30% and 37.5% for those 65 to 79, and 46.3% and 42.6% for those >80. No
factors analyzed were associated with loss of primary functional patency of BCAVFs.
Conclusions: Age did not affect usability, primary or secondary patency of either RCAVFs or BCAVFs. Although patient
selection is important, even patients>80 years who are considered suitable for surgical placement of access should not be
denied a RCAVF solely because of age. (J Vasc Surg 2008;47:144-50.)The increase in demand for hemodialysis in both North
America and Europe is attributable to the large increases in
end-stage renal failure (ESRF) in patients aged 65
years.1-4 It has been suggested that the uptake of dialysis in
the population aged80 years has also contributed greatly
to this phenomenon.5,6 Between 1996 and 2003 in the
United States, the number of patients starting dialysis per
year in this age group has almost doubled, from 7054 to
13,577.5 Furthermore in 1980, only 7.6% of new ESRF
patients were 75 years; whereas in 2004, 25% of new
patients were in this age group.1
Guidelines for vascular access recommend that the
radiocephalic autogenous fistula (RCAVF) should be the
first-choice access procedure for patients commencing di-
alysis.7 Concern has been raised, however, that this is not
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144appropriate for all age groups.8 In general, outcomes for
RCAVFs and brachiocephalic arteriovenous fistulas
(BCAVFs) vary considerably in the literature and are diffi-
cult to interpret and compare owing to different patient
characteristics and reporting of outcomes.9 Meta-analysis
data of 30 mainly retrospective studies suggests that15%
of all attempted RCAVFs fail in the early postoperative
period.10 The primary and secondary patency rates of AVFs
in this analysis at 1 year were 62.5% (95% confidence
interval [CI], 54% to 70.3%) and 66% (95% CI, 58.2% to
73.0%).10 The reported patency of BCAVFs is comparable
with that of RCAVFs.11
However, a prospective study by the same authors of
the RCAVF meta-analysis found that when “use for dialy-
sis” is used as an outcome, patency rates are much worse12:
41% of RVACFs had failed by 6 weeks, and primary patency
at 1 year was 33%. Similarly in an earlier North American
study, only 34% of patients developed a RCAVF adequate
for dialysis.13 In this study, only 12% of RCAVFs con-
structed in the group aged 65 years were adequate to
support dialysis compared with 54% of BCAVFs.13
A number of studies have observed mixed results in
comparisons of outcomes in RCAVFs and BCAVFs in
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usually 65 years.8 Lok et al14 observed that older patients
generally had a greater risk of AVF maturation failure
(hazard ratio, 1.7) than those 65, but that secondary
patency was equivalent between age groups for all types of
autogenous access. A recent meta-analysis of this literature,
however, found an increase risk of failure of RCAVFs
compared with BCAVFs (odds ratio, 1.525) in patients
65 years and has recommended that this finding should
be considered when planning access surgery.8 Given that
the median age of patients with ESRF in the United States
approaches 65 years,1 the adoption of such recommenda-
tions has major implications for access programs.
To our knowledge, however, no studies have specifi-
cally considered outcomes in those 80 years. Given that
the prevalence of comorbidity is high in those 80 years,5
we hypothesized that poor outcomes in this subgroup
within the “over 65” age group have skewed results and
resulted in the worse outcomes for RCAVFs compared with
BCAVFs observed in the “elderly” in most studies.8 The
aim of this study is therefore to examine the outcomes of
RCAVFs and BCAVFs (use for dialysis, primary and sec-
ondary functional patency) after primary access (first at-
tempted surgical procedure) in patient the age groups of
65, 65 to 79, and 80 years.
METHOD
Patients. All patients undergoing the first attempted
first surgical access procedure between January 1, 2000,
and December 31, 2005, were identified, and patients
undergoing an autogenous RCAVF or BCAVF were in-
cluded in the study. All cases were retrospectively identified
using the theater logs, and patient records were interro-
gated. Recorded was information on age, ethnic group,
diabetic status (oral hypoglycemics or insulin, or both),
hypertension (use of antihypertensives), human immuno-
deficiency virus (HIV) status, intravenous drug use, time-
liness of referral, and whether the patient had at any time
received hemodialysis before the primary access procedure
by way of a temporary central venous dialysis catheter.
Accurate information on tobacco use was not available in
the case notes and was not included.9
Preoperative assessment and operative procedures.
The first fistula was placed preferentially in the nondomi-
nant arm and in the most distal position that appeared
feasible when clinically assessed by a consultant surgeon.
Clinical assessment involved a review of the patient’s his-
tory of prior peripheral and venous cannulation, followed
by a physical examination. Patients with a palpable radial
pulse and a visible cephalic vein 2 mm from the wrist to
antecubital fossa with a tourniquet in the nondominant
forearm underwent RCAVF formation. Patients without
these features, but with palpable brachial pulse and a ce-
phalic vein 2 mm in the upper arm, underwent BCAVF
formation.
No imaging was used to determine if there was any
pre-existing central venous stenosis before surgery. Preop-
erative duplex ultrasonography (DUS) was only used whensuch clinical features were absent in the nondominant arm.
This method of clinical rather than mandatory DUS preop-
erative assessment is supported by the literature.15,16 When
the preoperativeDUS did not show anatomy favorable with
the construction of a RCAVF or BCAVF,17 but did dem-
onstrate a suitable basilic vein, the patient was offered a
transposed brachiobasilic arteriovenous fistula (BBAVF).18
Patients without suitable autologous anatomy had upper
arm brachioaxillary access grafts.
Both RCAVFs and RCAVFs were created using an end
of the cephalic vein to the side of the artery anastomosis
with continuous 6-0 synthetic monofilament. Operations
were done under local anesthesia as a preference.
Outcome. Patients were deemed to have proceeded to
hemodialysis if they had received at least one hemodialysis
session, regardless of how vascular access was provided for
that session (dialysis catheter, autogenous fistula, or pros-
thetic graft). We identified the number of patients who had
a surgical access procedure but did not proceed to hemo-
dialysis, and the reason for nonproceeding in each case,
such as a different form of renal replacement (ie, peritoneal
dialysis or transplantation) or death before commencing
renal replacement. Those patients who never had hemodi-
alysis were excluded from functional patency calculations
because the simple presence of a thrill within a fistula does
not determine whether a fistula can be used for dialysis.19
A successful fistula was defined as one that had been
used for hemodialysis. Primary functional patency was de-
fined as the interval from the time of access placement until
any intervention designed to maintain or re-establish pa-
tency, access thrombosis, or time of measurement of pa-
tency, and was expressed as a percentage of all the AVFs
attempted in the hemodialysis population at 1 and 2 years.9
Interventions included angioplasty, thrombectomy, and
surgical revision of the fistula.
Secondary functional patency was defined as the inter-
val from the time of access placement until access abandon-
ment, thrombosis, or time of patency assessment, including
interventions designed to re-establish functionality in
thrombosed access, and expressed as a percentage of all the
AVFs attempted in the hemodialysis population 1 and 2
years.
The dates of death or transplantation were recorded as
relevant. Patients who underwent transplantation or died
were considered as lost to follow-up and were censored for
all survival analysis.
Statistical analysis. Logistic regression was used to
assess the effect of age and fistula type on the progression of
a patient onto dialysis after access surgery. Logistic regres-
sion was also used to examine the influence of preoperative
DUS, age, diabetes, hypertension, sex, ethnic group, and
prior hemodialysis on whether a fistula was ever used in the
dialysis population. We performed a Cox proportional haz-
ards regression analysis to examine the influence of preop-
erative DUS, age, diabetes, hypertension, sex, ethnic
group, and prior hemodialysis on the primary and second-
ary patency of RCAVFs and BCAVFs (considered sepa-
rachio
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log plots.
To compare our findings with that of the recent meta-
analysis, we also evaluated the patency of RCAVFs com-
pared with BCAVFs for each age group using life tables and
Kaplan-Meier survival analysis. The two groups were com-
pared using a log-rank test. Statistical analysis was per-
formed using Software Package for the Social Sciences
(version 12.0 for Windows, SPSS Inc, Chicago, Ill). A P
.05 was considered statistically significant.
RESULTS
Patients. During the study period, 716 adults under-
went the first access procedure for hemodialysis, and 658
had a RCAVF or BCAVF. A basilic vein transposition was
done in 21 patients (2.9%), and 37 (5.1%) had an access
graft as a primary procedure. There was no effect of age
group on type of operation used for first access (P  .874,
2 test). Overall, 50.4% of first-placed fistulas were sited at
the wrist (RCAVF).
Table I summarizes the patient demographics for the
658 patients undergoing RCAVF and BCAVF formation
(the study population) for each age group. The median age
was 68.5 years (IQR, 54.4 to 76.5 years). No patients were
positive for HIV, and only one patient (65 years,
BCAVF) had a history of intravenous drug use. Median
follow-up was 24.0 months (IQR, 11.7 to 47.2 months).
The three age groups were well matched apart from ethnic-
ity.
Overall, 161 patients (24.5%) had a preoperative DUS,
and age did not influence this (P  .903 2). Preoperative
DUS was done in 21.6% patients (78) undergoing RCAVF
creation, and there was no difference among the age groups
(65, 23.6%; 65 to 79, 21.6%;80, 14.9%; P .443 2).
Of patients undergoing a BCAVF, 27.9% (83) had a pre-
operative DUS, and once again, this did not differ among
the age groups (65, 23.6%; 65 to 79, 29.8%;80, 34.7%;
Table I. Demographics
Demographics
65 y (n  288),
No. (%)
Female sex 123 (42.7)
Diabetes 95 (32.9)
Hypertension 178 (61.8)
Referral 3 months before first HD 58 (20.1)
Line HD before surgical access 125 (43.4)
Ethnic group
White 246 (85.4)
Asian 17 (5.90)
Black 15 (5.20)
Unclassified 10 (4.41)
Fistula type
RCAVF 161 (55.9)
BCAVF 127 (44.1)
Proceeded to dialysis (any modality) 247 (85.8)
HD, Hemodialysis; RCAVF, radiocephalic arteriovenous fistula; BCAVF, b
*Statistically significant.P  .260 2). Of interest was that the 24 patients (25%) inthe 80 group who had DUS were more likely to have a
BCAVF (n 17) than a RCAVF (n 7, P .025 2). This
was not true of the 65 group (P  .997 2) or the 65 to
79 age group (P  .121 2).
When patients who had a RCAVF were compared with
the BCAVF group, there was no difference in age (P 
.063), hypertension (P  .578), ethnicity (P  .06), prior
hemodialysis (P  .195), late referral (P  .073), or pre-
operative DUS (P  .06). Within the RCAVF group,
however, the proportion of men was significantly (P 
.0001) higher (65.9%) than in the BCAVF population
(45.5%). Furthermore, the proportion of diabetic patients
was lower (P  .005) in the RCAVF group (27.4%) com-
pared with the BCAVF group (37.7%).
Hemodialysis population. Of the 658 adults under-
going RCAVF or BCAVF formation, 564 (85.7%) went on
to receive hemodialysis, and 94 did not. The median age of
the hemodialysis population was 68.7 years (IQR, 54.5 to
76.5 years). Not proceeding to dialysis was not associated
with any age group (P  .398) or fistula types (P  .101).
The reasons the 94 patients did not proceed to dialysis
included renal replacement was not yet required in 53
(56.4%), 19 (20.2%) had died, and 22 (23.4%) had alterna-
tive renal replacement (peritoneal dialysis in 17, transplan-
tation in 5).
Successful use of fistulas in the hemodialysis
population. Table II summarizes the successful use rates
of RCAVFs and BCAVFs for each age group. Of RCAVFs
in the hemodialysis population, 160 (54%) were success-
fully used for dialysis. This rate was 10% higher in the
groups aged 65 to 79 and 80 years than in the 65
group, but the difference was not significant (P  .391).
We found that the only factor associated with failure of a
RCAVF to be used was female sex (OR, 2.24; 95% CI,
1.387 to 3.638; P .001). Dialysis was successful through
141 of the BCAVFs (54.2%). The only factor associated
with failure of a BCAVF to be used for dialysis was diabetes
65 to 79 y (n  274),
No. (%)
80 y (n  96),
No. (%) P (2)
120 (43.8) 42 (43.8) .963
93 (33.9) 23 (24.0) .178
166 (60.6) 47 (48.9) .075
60 (21.9) 25 (26.0) .477
111 (40.5) 44 (45.8) .614
.001*
236 (86.1) 93 (96.9)
1 (0.37) 0
9 (3.28) 0
26 (9.49) 2 (2.08)
.453
153 (55.8) 47 (49.0)
121 (44.2) 49 (51.0)
238 (86.2) 79 (82.3) .545
cephalic arteriovenous fistula.(OR, 2.095; 95% CI, 1.261 to 3.482; P  .004). Of
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outcome, although once again, this difference did not reach
statistical significance.
Patency of fistulas in the hemodialysis population.
The overall primary functional patency rates at 1 and 2 years
were 46.4% and 32.1% for RCAVFs and 47.7% and 37.3%
for BCAVFs.
The patency rates at 1 and 2 years for RCAVF were
46.0% and 27.1% for the 65 group; 47.0% and 36.0% for
the 65 to 79 group, and 45.7% and 38.1% for the 80
group (Fig 1). The secondary patency rates at 1 and 2 years
were 46.1% and 27.8% for the 65 group; 47.8% and
37.5% for 65 to 79 group, and 47.8% and 39.9% for the
80 group (Fig 2). The age groups did not differ signifi-
cantly in primary (log-rank P  .3508) or secondary (log-
rank P .2761) patency. Using Cox regression analysis, we
identified that female sex (HR, 1.657; 95% CI, 1.246 to
2.205; P  .001) and hemodialysis before surgically cre-
ated access (HR, 1.331; 95%CI, 1.007 to 1.759; P .031)
were associated with loss of primary functional patency of
RCAVFs. Both female sex (HR, 1.625; 95% CI, 1.220 to
2.164; P  .001) and prior hemodialysis (HR, 1.359; 95%
CI, 1.026 to 1.801; P  .033) were also associated with
loss of secondary patency of RCAVFs. Age group (65, 65
to 79,80) did not influence loss of primary functional or
secondary functional patency.
The primary functional patency rates for BCAVF at 1
Table II. Successful use of an arteriovenous fistula for
dialysis in each age group
Fistula
type 65 y (%) 65 to 79 y (%) 80 y (%) P (2)
RCAVF 68/137 (49.6) 75/131 (57.3) 21/36 (58.3) .391
BCAVF 55/110 (50) 64/107 (59.8) 22/43 (51.2) .317
RCAVF, radiocephalic arteriovenous fistula; BCAVF, brachiocephalic arte-
riovenous fistula.
Fig 1. The impact of age on primary functional patency of radio-
cephalic arteriovenous fistulas in the hemodialysis population. Age
had no significant effect on patency (log-rank P .3508). Survival
curves in the figure were terminated at 2 years and remained
reliable at that time.and 2 years were 39.3% and 31.0% for the 65 group,53.30% and 37.5% for the 65 to 79 group, and 46.3% and
42.6% for the 80 group (Fig 3). The secondary patency
rates at 1 and 2 years were 41.0% and 33.6% for the 65
group; 55.7% and 39.2% for the 65 to 79 group, and 46.3%
and 42.6% for the 80 group (Fig 4). No significant
difference for primary (log-rank P  .1453) or secondary
(log-rank P  .2470) patency was found among the age
groups, and no factors could be identified that were asso-
ciated with loss of primary or secondary patency of
BCAVFs. Once again, age group (65, 65 to 79,80) did
not influence loss of primary functional or secondary func-
tional patency.
Comparing the performance of each fistula type in
each age group. When we compared functional patency
between RCAVFs and BCVAFs for each age group, we
found no significant differences. In the 65 group, there
was no difference in primary (P  .6749) or secondary
Fig 2. The impact of age on secondary functional patency of
radiocephalic arteriovenous fistulas (RCAVFs) in the hemodialysis
population. Age had no significant effect on patency (log-rank P
.2761). Survival curves in the figure were terminated at 2 years and
remained reliable at that time.
Fig 3. The impact of age on primary functional patency of bra-
chiocephalic arteriovenous fistulas (BCAVFs) in the hemodialysis
population. Age had no significant effect on patency (log-rank P
.1453). Survival curves in the figure were terminated at 2 years and
remained reliable at that time.functional patency (P  .9399) between RCAVFs and
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79 years (primary P  .9766 and secondary P  .8288).
The primary and secondary functional patency of the
RCAVF and BCAVF in the 80 group is shown in Fig 5.
DISCUSSION
To our knowledge, this is the first peer-reviewed and
Medline indexed study to specifically consider and compare
functional outcomes of autogenous fistulas in the rapidly
expanding 80 age group. More than half the patients in
our study were aged65 years, and almost 15% of the total
study population was 80 years. These demographics are
in keeping with the predicted increase in demand for renal
replacement therapy in elderly patients.20 Although patient
survival is lower in the 80 population,21 the cost of
dialysis is similar to other life-extending interventions that
preserve the quality of life in elderly patients.21 Demand is
set to further increase, so it is important to establish if the
current clinical access guidelines are appropriate in this age
group, particularly in light of the meta-analysis data sug-
gesting outcomes of RCAVFs are worse than BCAVFs in
the elderly.8
It is noteworthy that only 85.7% of patients undergoing
their first attempted RCVAF or BCAVF actually ever re-
ceived hemodialysis either with that access, a dialysis cath-
eter, or a subsequent surgically created access. Most of the
patients in this nonhemodialysis group had not yet required
renal replacement therapy at a median of 24 months after
access surgery. Planning and delivering optimal predialysis
care, with timely surgical access for hemodialysis is impor-
tant and is associated with reductions in mortality and
morbidity.22 This requires not only early nephrology refer-
ral but also the appropriate number of surgical sessions to
create and maintain dialysis access. Planning must allow for
such a nonproceed rate.
In our study, we attempted RCAVFs or BCAVFs in
92% of patients undergoing the first access procedure for
Fig 4. The impact of age on secondary functional patency of
brachiocephalic arteriovenous fistulas (BCAVFs) in the hemodial-
ysis population. Age had no significant effect patency (P  .2470
log-rank). Survival curves in the figure were terminated at 2 years
and remained reliable at that time.dialysis. Rates of RCAVFs and BCAVFs do not fall withage. In the planning of RCAVF and BCAVF surgery, only
161 patients (24.5%) had a preoperative DUS. Although it
has been suggested that all patients should have imaging
before access surgery,23 evidence suggests that clinical ex-
amination alone gives equivalent results. In a United King-
dom study, 145 patients underwent clinical examination by
a surgeon, followed by ultrasonographic mapping.15 The
surgeon felt able to site access clinically in 106 patients, but
considered DUS would be helpful in 39 (26.9%), a propor-
tion similar to what we have observed. Subsequent DUS by
a blinded clinician changed the proposed site of access of
only one of the 106 patients in whomDUS was considered
unnecessary. Furthermore, a recent randomized trial has
demonstrated no difference in technical success or cumu-
lative fistula survival between patients assessed clinically and
those assessed with DUS.16 In our study, logistic regression
and Cox regression analysis did not demonstrate any effect
of preoperative DUS on nonuse or functional patency,
respectively.
We found that overall, only 301 hemodialysis patients
(53.4%) had a fistula that was successfully used for dialysis.
Although the differences do not reach statistical signifi-
cance, slightly more fistulas are needled in the older age
groups, with the fistulas in the 65 to 79 age group perform-
ing best. This failure rate of 46.6% appears high compared
with the meta-analysis of RCAVF outcomes, which reports
a 15.3% early or technical failre rate,10 but is equivalent or
better than other studies that have defined fistula success in
terms of fistula usability.13,24,25
A number of factors have been associated with early
fistula failure, including demographic factors of age,14,26,27
female sex,14,25-28 already commenced dialysis,29 comor-
bidity (diabetes11,27,28), and more recently, the anatomic
factors of radial artery diameter,30,31 intima-media thick-
ness,32 and cephalic vein size.33,34 In this study, we found
that female sex alone was associated with nonuse of a
RCVAF. This is likely to relate to the smaller vessel diam-
eter found in women, although female sex has itself been
recognized as an independent risk factor for failure.25 Fur-
thermore, we found only diabetes was associated with
nonuse of BCAVF, which is consistent with other studies
that have examined BCAVFs independently.11
We hypothesized that functional outcomes for
RCAVFs would be worse than BCAVFs in patients 80
years, yet this study did not demonstrate any effect of age
on outcomes for either procedure. Indeed, factors associ-
ated with the loss of primary and secondary patency of
RCAVF were female sex and prior hemodialysis using a
central venous catheter, factors well-recognized in the lit-
erature.35
A number of studies have specifically examined the
effect of age on outcome, with conflicting results,8 but
none have considered the 80 age group. Lok et al14
demonstrated excellent and equivalent cumulative access
survival rates at 1 year of 75.1% in the 65 patients and
79.7% the65 age group for all autogenous fistulas. In the
RCAVF group, however, the authors reported 1-year cu-
mulative survival rates of 83.5% in the 65 patients com-
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Lok et al also found that age was also associated with early
failure of RCAVFs.14 Conversely, Golledge et al37 found
that younger patients had a higher risk of RCAVF failure in
the first month. Several other studies, however, have found
that age does have a negative impact on RCAVF out-
come.38,39 Increased age has been associated with increase
intima-media thickness32 and lower fistula flow rates,36
both associated with fistula failure.
Given the lack of concordance in the literature, a recent
meta-analysis set out to establish whether RCAVFs have the
same risk of failure in elderly and nonelderly patients, and
whether RCAVFs have the same risk of failure as more prox-
imal access.8 That analysis found that an increased risk of
failure of RCAVFs in older patients. The authors included 13
studies published during a period of 10 years with various
definitions of fistula failure and patency; however, only 10 of
the 13 studies specifically compared patency of RCAVFs of
younger adults with “elderly” adults. Elderly was defined
most commonly as 65 years, but in one article included in
the analysis, “elderly” was defined as “older than 50 years”
and in three articles as “older than 70 years.” Given the
heterogeneity of reporting and small number of trials in-
cluded, we would not implement the authors’ recommenda-
tion that elderly patients should have BCAVF formed in
preference to a RCAVF, especially in light of our own find-
ings. Indeed the suggestion that elderly patients have signifi-
cant benefit from BCAVF compared with RCAVF has not
been upheld by our data for either the group aged 65 to 79
years or the 80 group (Fig 5).
Bias within patient selection affects all nonrandomized
studies, and we acknowledge that this may explain why we
have observed equivalence between the age groups and
fistula sites. More men and fewer diabetic patients had
RCAVFs. It is difficult outside of a randomized study to
separate whether these factors simply confound the clinical
or anatomic selection of site or have independently influ-
Fig 5. The impact of radiocephalic arteriovenous fistula
and (B) secondary functional patency in the hemodialysis
terminated at 2 years and remained reliable at that time.enced the surgeon’s decision to choose a type of fistula.Another weakness of this study is that we do not know
what proportion of all hemodialysis patients are not offered
any surgical access procedure, although we believe it to be
low. It is conceivable that, compared with the other age
groups, a larger proportion of patients aged 80 receive
hemodialysis using a dialysis catheter and a fistula is never
attempted. The policy of our unit, however, is to minimize
the number of patients who undergo dialysis through a
central venous catheter, and there are no explicit criteria for
excluding patients from surgically created dialysis access.
Nevertheless, it could be argued that we may have selected
out only the patients most likely to do well in the older age
groups, whereas not attempting a surgical access procedure
in a younger patient would be unlikely.
Prospective randomized trials in access surgery are
scarce.40 A randomized, controlled trial comparing
RCAVFs with BCAVFs in the elderly population in whom
either is anatomically suitable is required to definitively
answer the question of which is the more appropriate
procedure. However, it is incontrovertible that in our
hands, patients65 suitable for any form of surgical access
should not automatically be offered a BCAVF as a first-
access procedure. We will continue to advocate the use of
RCAVFs in those patients in whom it appears clinically
appropriate.
CONCLUSION
Older patients in this series have equivalent RCAVF
and BCAVF outcomes. Female sex is an important risk
factor for both RCAVF nonuse and loss of patency. Al-
though patient selection is important, elderly patients con-
sidered suitable for surgical placement of access should not
be denied a RCAVF solely because of their age.
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